Spots Global Cancer Trial Database for famitinib
Every month we try and update this database with for famitinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Famitinib in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC) | NCT02356991 | Non-Small Cell ... | Famitinib Placebo | 18 Years - 70 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor | NCT04346381 | Solid Tumor | Camrelizumab Famitinib | 18 Years - 75 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer | NCT05176080 | Metastatic Brea... | Famitinib SHR6390 Fulvestrant | 18 Years - 75 Years | Henan Cancer Hospital | |
| A Phase I Study of Famitinib Malate in Patients With Solid Tumor | NCT01762280 | Advanced Solid ... | Famitinib Malat... | 18 Years - 65 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| A Trial of SHR-1701 in Combination With Famitinib in Patients With Advanced Solid Tumors | NCT04679038 | Solid Tumor | SHR-1701 Famitinib | 18 Years - | Jiangsu HengRui Medicine Co., Ltd. | |
| Cancer Genome Study Using Samples From Patients Treated on Clinical Trial SHR1020-SHR-1210-II-OS | NCT03997747 | Osteosarcoma | cytology specim... | 12 Years - | Peking University People's Hospital | |
| A Trial of Famitinib in Patients With Failure of First-Line Treatment For Intrahepatic Cholangiocarcinoma | NCT04479904 | Intrahepatic Ch... | Famitinib | 18 Years - 75 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Epigenetic Biomarker for Advanced Osteosarcoma Using Famitinib and Camrelizumab | NCT03919539 | Drug Resistance... Biomarkers for ... | 5hmc testing | 12 Years - | Peking University People's Hospital | |
| A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor | NCT01994213 | Gastroenteropan... | Famitinib | 18 Years - 75 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma | NCT04888429 | Sarcomatoid Car... | Camrelizumab Famitinib | 18 Years - 75 Years | Tongji Hospital | |
| Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer | NCT04355858 | Breast Cancer Metastatic Canc... | SHR7390 Famitinib SHR3162 Pyrotinib Capecitabine SHR1210 Everolimus Nab paclitaxel SHR2554 SHR3680 SHR6390 SHR1701 SERD AI VEGFi | 18 Years - 75 Years | Fudan University | |
| Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer | NCT05176080 | Metastatic Brea... | Famitinib SHR6390 Fulvestrant | 18 Years - 75 Years | Henan Cancer Hospital | |
| A Trial of SHR-1701 in Combination With Famitinib in Patients With Advanced Solid Tumors | NCT04679038 | Solid Tumor | SHR-1701 Famitinib | 18 Years - | Jiangsu HengRui Medicine Co., Ltd. | |
| A Study of Famitinib in Patients With Advanced Colorectal Cancer | NCT01762293 | Colorectal Canc... Colorectal Canc... Colorectal Canc... | Famitinib placebo | 18 Years - 70 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| A Trial of Famitinib in Patients With Failure of First-Line Treatment For Intrahepatic Cholangiocarcinoma | NCT04479904 | Intrahepatic Ch... | Famitinib | 18 Years - 75 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer | NCT04355858 | Breast Cancer Metastatic Canc... | SHR7390 Famitinib SHR3162 Pyrotinib Capecitabine SHR1210 Everolimus Nab paclitaxel SHR2554 SHR3680 SHR6390 SHR1701 SERD AI VEGFi | 18 Years - 75 Years | Fudan University | |
| Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer | NCT04355858 | Breast Cancer Metastatic Canc... | SHR7390 Famitinib SHR3162 Pyrotinib Capecitabine SHR1210 Everolimus Nab paclitaxel SHR2554 SHR3680 SHR6390 SHR1701 SERD AI VEGFi | 18 Years - 75 Years | Fudan University | |
| Safety and Efficacy Study of Famitinib in Patients With Advanced Colorectal Adenocarcinoma（FACT） | NCT02390947 | Colorectal Canc... Colorectal Canc... | Famitinib Placebo | 18 Years - 75 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer | NCT05176080 | Metastatic Brea... | Famitinib SHR6390 Fulvestrant | 18 Years - 75 Years | Henan Cancer Hospital | |
| A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer. | NCT04733417 | Advanced Breast... Metastatic Brea... | SHR6390 famitinib | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| A Trial of Famitinib in Patients With Failure of First-Line Treatment For Intrahepatic Cholangiocarcinoma | NCT04479904 | Intrahepatic Ch... | Famitinib | 18 Years - 75 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| A Phase I Study of Famitinib Malate in Patients With Solid Tumor | NCT01762280 | Advanced Solid ... | Famitinib Malat... | 18 Years - 65 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Epigenetic Biomarker for Advanced Osteosarcoma Using Famitinib and Camrelizumab | NCT03919539 | Drug Resistance... Biomarkers for ... | 5hmc testing | 12 Years - | Peking University People's Hospital | |
| Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced Osteosarcoma | NCT04044378 | Effect of Drugs Progression Pediatric Cance... | Famitinib Ifosfamide Camrelizumab | 12 Years - | Peking University People's Hospital | |
| A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer. | NCT04733417 | Advanced Breast... Metastatic Brea... | SHR6390 famitinib | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma | NCT05020925 | Nasopharyngeal ... | SHR-1701 Famitinib | 18 Years - 75 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| A Trial of SHR-1701 in Combination With Famitinib in Patients With Advanced Solid Tumors | NCT04679038 | Solid Tumor | SHR-1701 Famitinib | 18 Years - | Jiangsu HengRui Medicine Co., Ltd. | |
| Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors | NCT03827837 | Renal Cell Carc... Urothelial Carc... Cervical Cancer Ovarian Cancer ... Endometrial Can... | SHR-1210 Famitinib | 18 Years - | Jiangsu HengRui Medicine Co., Ltd. | |
| A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor | NCT01994213 | Gastroenteropan... | Famitinib | 18 Years - 75 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma | NCT04888429 | Sarcomatoid Car... | Camrelizumab Famitinib | 18 Years - 75 Years | Tongji Hospital | |
| Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor | NCT04346381 | Solid Tumor | Camrelizumab Famitinib | 18 Years - 75 Years | Jiangsu HengRui Medicine Co., Ltd. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
